Atea Pharma climbs on FDA's fast-track tag for dengue treatment

Atea Pharmaceuticals

26/09/2022 14:00

** Shares of Atea Pharmaceuticals Inc  AVIR.O  up 2.6% at
$5.95 premarket
    ** U.S. FDA grants "fast track" designation to company's
experimental drug, AT-752, for treating dengue virus infection
 urn:newsml:reuters.com:*:nGNX3YZgwC
    ** Drug is currently being studied in a mid-stage trial
    ** Dengue is a mosquito-borne virus and affects up to 400
mln people annually 
    ** FDA's fast-track program facilitates the expedited
development and review of new drugs or biologics that can treat
serious conditions and demonstrate potential to address unmet
medical needs
    ** As of last close, stock down ~35% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com))